North East and North Cumbria
ICS Formulary
 
back
8 Malignant disease and immunosuppression
08-03-04-01 Breast cancer

Abemaciclib Verzenios®
Formulary

  • 50mg, 100mg and 150mg tablets

  • Approved as an options for treating locally advanced or metastatic, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer as first endocrine-based therapy in adults in line with NICE

  • Approved with fulvestrant for treating hormone receptor-positive, HER2 negative advanced breast cancer after endocrine therapy in line with NICE 


 

Link  MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases
Link  NICE TA 563: Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA725: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Link  NICE TA810: Abemaciclib with endocrine therapy for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence

Red View adult BNF  View SPC online  View childrens BNF  HCD
Alpelisib Piqray®
Formulary
  • 50mg, 150mg and 200mg tablets
  • Approved with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated, locally advanced or metastatic breast cancer in adults in line with NICE
Link  NICE TA816: Alpelisib with fulvestrant for treating hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer

Red View adult BNF  View SPC online  View childrens BNF  HCD
Anastrozole
Formulary
Link  NICE CG164: Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

Green plus View adult BNF  View SPC online  View childrens BNF
Exemestane
Formulary

Green plus View adult BNF  View SPC online  View childrens BNF
Fulvestrant Faslodex®
Formulary
Link  NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer

Red View adult BNF  View SPC online  View childrens BNF
Letrozole
Formulary

Green plus View adult BNF  View SPC online  View childrens BNF
Palbociclib Ibrance®
Formulary
  • 75mg, 100mg & 125mg capsules
  • Approved for use with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE
  • Approved with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy in line with NICE
Link  NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA836: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Link  MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases

Red View adult BNF  View SPC online  View childrens BNF  HCD
Raloxifene
Formulary

60mg tablets


Green plus View adult BNF  View SPC online  View childrens BNF
Ribociclib Kisqali®
Formulary
  • 200mg tablets
  • Approved for use with an aromatase inhibitor for the treatment of previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer in line with NICE and NHS England Commissioning Policy
  • Approved for treating hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer in adults who have had previous endocrine therapy in line with NICE

 

Link  NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Link  NICE TA687: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Link  MHRA Drug Safety Update (June 2021): CDK4/6 inhibitors (abemaciclib▼, palbociclib▼, ribociclib▼): reports of interstitial lung disease and pneumonitis, including severe cases

Red View adult BNF  View SPC online  View childrens BNF  HCD
Tamoxifen
Formulary
  • Approved formulations include:
    • 10mg and 20mg tablets;
    • 10mg in 5ml sugar free oral solution.


Green plus View adult BNF  View SPC online  View childrens BNF